Press releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Mar 4, 2013
Boston Scientific Corporation (NYSE: BSX) is scheduled to present sponsored research at the 62nd Annual Scientific Session of the American College of...
-
Feb 21, 2013
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2013 RBC Capital Markets Healthcare Conference on February 26 in New...
-
Feb 20, 2013
(Feb. 20, 2013 US Time) Boston Scientific Corporation (NYSE: BSX) subsidiary Boston Scientific Japan K.K. has reached an agreement with Fukuda Denshi Co., Ltd. to market and sell the Boston...
-
Feb 20, 2013
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Citi 2013 Global Healthcare Conference on February 25 in New York....
-
Feb 12, 2013The Next Advance in Durable Polymer Stent Technology from Boston Scientific is Now Available in Europe and Other Select Geographies
Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval for the Promus PREMIER™ Everolimus-Eluting Platinum Chromium Coronary Stent...
-
Feb 6, 2013
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2013 Leerink Swann Global Healthcare Conference on February 13 in New York....
-
Jan 29, 2013Organizations Team up to Raise awareness and Make a Call to Action for European Governments to Develop Comprehensive Chronic Pain Treatment Programs
Paris (January 29, 2013) – Boston Scientific Corporation (NYSE:BSX) today released results of a survey of more than 1,000 chronic pain sufferers across Europe that suggest millions of...
-
Jan 29, 2013
Boston Scientific Corporation (NYSE: BSX) announces financial results for the fourth quarter and full year ended December 31, 2012, as well as sales...
-
Jan 17, 2013
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the fourth quarter and full year ended...
-
Jan 16, 2013
The first patient has been treated in the Boston Scientific Corporation (NYSE: BSX) ZERO AF clinical trial to evaluate the safety and effectiveness of...
-
Jan 8, 2013
Boston Scientific Corporation (NYSE: BSX) will host an Investor Day meeting on Tuesday, February 12, 2013. The meeting is scheduled to begin with a...
-
Dec 20, 2012
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 31st Annual J.P. Morgan Healthcare Conference in San Francisco on...
-
Dec 17, 2012Company Begins Evaluation of its Next Generation Pacing Leads
The first patient has been implanted with the Boston Scientific Corporation (NYSE: BSX) next generation INGEVITY™ pacing leads in a clinical trial...
-
Dec 12, 2012Close the Gap Initiative Urges Fans to Learn Their Risk Factors for Heart Disease and Take Responsibility for Their Heart Health
The Boston Scientific Corporation (NYSE: BSX) health equity initiative, Close the Gap, will once again be the title sponsor of the Crossroads Classic,...
-
Dec 7, 2012World's First and Only System with 32 Contacts and 32 Dedicated Power Sources is Designed to Provide Pain Relief to a Broad Spectrum of Chronic Pain Patients
Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval and has begun the European market launch of the Precision Spectra™ Spinal...
-
Dec 4, 2012Study to Compare Clinical Outcomes of Self-Expanding Metal Stents (SEMS) Versus Plastic Stents for the Treatment of Biliary Strictures Caused by Chronic Pancreatitis
The first patient has been enrolled in a Boston Scientific Corporation (NYSE: BSX) study comparing the WallFlex® Biliary RX Fully Covered...
-
Nov 30, 2012
The first patient has been enrolled in the Boston Scientific Corporation (NYSE: BSX) EVOLVE II clinical trial, which is designed to further assess the...
-
Nov 20, 2012Devices Projected to Have up to Twice the Longevity of Comparable Products
Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval for increased longevity projections for the INCEPTA™, ENERGEN™, PUNCTUA™,...
-
Nov 8, 2012Company to Consolidate Natick, Mass. Headquarters into Existing Marlborough Site; Facility Expansion to Create Collaborative Campus Setting; Consolidation Expected to be Completed by Mid-Summer 2014
Natick, Mass. (November 8, 2012) – Boston Scientific Corporation (NYSE:BSX) announces it will consolidate its Natick, Mass. global headquarters into its Marlborough, Mass. location, where a new...
-
Nov 8, 2012Company to Strengthen Hypertension Program with Acquisition of Renal Denervation Technology
Boston Scientific Corporation (NYSE: BSX) is extending its reach into the strategically critical renal denervation market by signing a definitive...
-
Nov 6, 2012MADIT-RIT Clinical Trial Study Results Published Today in the New England Journal of Medicine
Boston Scientific Corporation (NYSE: BSX) and the University of Rochester Medical Center presented positive results from the Multicenter Automatic...
-
Nov 1, 2012Appointment Completes Company's CEO Transition Plan; Mahoney Replaces Interim CEO William H. (Hank) Kucheman
In an expected move that follows a previously announced leadership transition period, Boston Scientific Corporation (NYSE: BSX) today named Michael F....
-
Oct 31, 2012This Innovative Bioabsorbable Coating is the First to Complete Absorption Shortly after Drug Elution Ends at Three Months
Boston Scientific Corporation (NYSE: BSX) received CE Mark approval for the SYNERGY™ Everolimus-Eluting Platinum Chromium Coronary Stent System...
-
Oct 24, 2012
Boston Scientific Corporation (NYSE:BSX) has received approval to update the directions for use (DFU) labeling for PROMUS Element™ and PROMUS...
-
Oct 23, 2012PLATINUM Long Lesion Clinical Results Presented at TCT 2012 Show No Heart Attack or Stent Thrombosis at Two-Year Follow-Up
Boston Scientific Corporation (NYSE: BSX) reports clinical endpoint data from the PLATINUM Long Lesion trial, demonstrating positive outcomes for the...